E
Eugene Park
Researcher at University of Cambridge
Publications - 15
Citations - 1048
Eugene Park is an academic researcher from University of Cambridge. The author has contributed to research in topics: Leukemia & B cell. The author has an hindex of 9, co-authored 15 publications receiving 930 citations. Previous affiliations of Eugene Park include University of Southern California & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
BCL6 enables Ph + acute lymphoblastic leukaemia cells to survive BCR–ABL1 kinase inhibition
Cihangir Duy,Christian Hurtz,Christian Hurtz,Seyedmehdi Shojaee,Leandro Cerchietti,Huimin Geng,Srividya Swaminathan,Lars Klemm,Soo-Mi Kweon,Rahul Nahar,Rahul Nahar,Melanie Braig,Eugene Park,Yong-Mi Kim,Wolf-Karsten Hofmann,Sebastian Herzog,Hassan Jumaa,H. Phillip Koeffler,J. Jessica Yu,Nora Heisterkamp,Thomas G. Graeber,Hong L Wu,B. Hilda Ye,Ari Melnick,Markus Müschen,Markus Müschen +25 more
TL;DR: It is demonstrated that targeted inhibition of BCL6 leads to eradication of drug-resistant and leukaemia-initiating subclones and the discovery of a novel mechanism of drug resistance, which is based on protective feedback signalling ofLeukaemia cells in response to treatment with TKI.
Journal ArticleDOI
Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia
Srividya Swaminathan,Lars Klemm,Lars Klemm,Eugene Park,Eugene Park,Elli Papaemmanuil,Anthony M. Ford,Soo-Mi Kweon,Daniel Trageser,Brian Hasselfeld,Nadine Henke,Jana Mooster,Huimin Geng,Klaus Schwarz,Scott C. Kogan,Rafael Casellas,David G. Schatz,Michael R. Lieber,Mel Greaves,Markus Müschen +19 more
TL;DR: It is demonstrated that AID and RAG1-RAG2 drove leukemic clonal evolution with repeated exposure to inflammatory stimuli, paralleling chronic infections in childhood.
Journal ArticleDOI
BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia
Christian Hurtz,Christian Hurtz,Katerina Hatzi,Leandro Cerchietti,Melanie Braig,Eugene Park,Yong-Mi Kim,Sebastian Herzog,Parham Ramezani-Rad,Hassan Jumaa,Martin C. Müller,Wolf-Karsten Hofmann,Andreas Hochhaus,B. Hilda Ye,Anupriya Agarwal,Brian J. Druker,Neil P. Shah,Ari Melnick,Markus Müschen,Markus Müschen +19 more
TL;DR: Clinical validation of this concept could limit the duration of TKI treatment in CML patients, which is currently life-long, and substantially decrease the risk of blast crisis transformation, as well as suggest that pharmacological inhibition of BCL6 may represent a novel strategy to eradicate LICs in C ML.
Journal ArticleDOI
Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia.
Eun Ji Gang,Yao-Te Hsieh,Jennifer Pham,Yi Zhao,Cu Nguyen,Sandra Huantes,Eugene Park,Khatija Naing,Lars Klemm,Srividya Swaminathan,Edward M. Conway,Louis M. Pelus,John D. Crispino,Charles G. Mullighan,Michael McMillan,Markus Müschen,Michael Kahn,Yong-Mi Kim +17 more
TL;DR: In this article, selective disruption of the CBP/β- and γ-catenin interactions using ICG-001 leads to differentiation of pre-B ALL cells and loss of self-renewal capacity.
Journal ArticleDOI
Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function
Daniel Trageser,Ilaria Iacobucci,Rahul Nahar,Cihangir Duy,Cihangir Duy,Gregor von Levetzow,Gregor von Levetzow,Lars Klemm,Lars Klemm,Eugene Park,Wolfgang Schuh,Tanja A. Gruber,Sebastian Herzog,Yong-Mi Kim,Wolf-Karsten Hofmann,Aihong Li,Clelia Tiziana Storlazzi,Hans-Martin Jäck,John Groffen,Giovanni Martinelli,Nora Heisterkamp,Hassan Jumaa,Markus Müschen,Markus Müschen +23 more
TL;DR: It is demonstrated that the pre–B cell receptor functions as a tumor suppressor upstream of IKAROS through induction of cell cycle arrest in Ph+ ALL cells, and IKarOS-mediated cell cycle exit is identified as the endpoint of an emerging pathway of pre– B cell receptor–mediated tumor suppression.